In the long term, we may succeed in therapeutically targeting the CRHR1 implicated in the HPA axis disruption in subjects with family risk for T2D and MDD, thereby reversing the HPA axis hyperactivity to a physiological state and preventing both disorders. The gene discussed is CRHR1; the disease is type 2 diabetes mellitus.